Ensysce Biosciences (ENSC) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ENSC Ensysce Biosciences

Watchlist

0.4279
+0.0149+3.61%

Close Jul 26 16:00 ET

0.4128
-0.0151-3.53%

Post 20:01 ET

3.25MMarket Cap-135P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Ensysce Biosciences To Host Symposium On Safer Analgesics At IASP 2024 World Congress; CEO Dr. Lynn Kirkpatrick To Introduce Event Featuring Pain Experts Dr. Lars Arendt-Nielsen And Dr. William Schmidt
BenzingaJul 23 08:10 ET
Express News | Ensysce Biosciences Inc - Agreement With Purisys LLC to Scale Manufacture of Company's Lead Opioid Use Disorder (Oud) Drug Candidate. Pf9001
ReutersJun 25 08:14 ET
Express News | Ensysce Biosciences Inc - Announces Partnership to Scale and Manufacture New Drug Candidate
ReutersJun 25 08:13 ET
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
BenzingaJun 21 08:22 ET
12 Health Care Stocks Moving In Thursday's After-Market Session
BenzingaJun 20 16:31 ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
BenzingaJun 18 16:31 ET

Comments

Jaguar8

Jun 6 07:28

NEWS

$Ensysce Biosciences(ENSC.US)$
Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program
Ensysce Biosciences (NASDAQ: ENSC) has achieved a critical milestone in its opioid use disorder (OUD) program. The company has selected PF9001, a lead drug candidate designed to reduce abuse potential and improve safety, particularly with lower cardiovascular risks compared to traditional treatments. The candidate will proceed to Investigational New Drug (IND) enabling studies, backed...

joeyboulevard

May 20 10:03

$Ensysce Biosciences(ENSC.US)$ we going to a dollar

Jaguar8

May 20 08:49

$Ensysce Biosciences(ENSC.US)$
NEWS
Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform
Ensysce Biosciences has renewed its collaboration with Quotient Sciences to advance the clinical development of its overdose protection platform, PF614-MPAR. This innovative opioid product, designed to prevent overdose by shutting off opioid release when too many pills are ingested, is undergoing a Phase 1b study to evaluate its efficacy a...